Homology Medicines Inc (FIXX) Down 2.26% in Premarket Trading

Monday, July 31, 2023 07:45 AM | InvestorsObserver Analysts

Mentioned in this article

Homology Medicines Inc (FIXX) Down 2.26% in Premarket Trading

Homology Medicines Inc (FIXX) has fallen Monday morning, with the stock falling -2.26% in pre-market trading to 1.3. FIXX's short-term technical score of 45 indicates that the stock has traded less bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 115 out of 146 industries, FIXX ranks higher than 60% of stocks. Homology Medicines Inc has risen 49.44% over the past month, closing at $0.85 on July 3. During this period of time, the stock fell as low as $0.84 and as high as $1.38. FIXX has an average analyst recommendation of Strong Buy. The company has an average price target of $8.00.

FIXX has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on FIXX!

See Full FIXX Report

Homology Medicines Inc has a Long-Term Technical rank of 41. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 59% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, FIXX ranks better than 130% of stocks.

Important Dates for Investors in FIXX:

-Homology Medicines Inc is set to release earnings on 8/21/2023. Over the last 12 months, the company has reported EPS of $-2.18. -We do not have a set dividend date for Homology Medicines Inc at this time. Click Here To Get The Full Report on Homology Medicines Inc (FIXX)